Endocarditis: Clinical Trials

6 trials for Endocarditis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 terminated. 6 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 46Terminated 6

Follow Endocarditis: new trials by email Literature Review of Endocarditis trials Research Report on Endocarditis

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)
Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline - Endocarditis
Phase 4TerminatedWest Virginia University52022-03-162026-05-05
Short-course Antibiotic Treatment in Gram-positive Cocci Infective Endocarditis
Antibiotics - Endocarditis, Bacterial
Phase 4TerminatedCarmen Olmos Blanco202021-01-262023-09-28
An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following Dental Procedures
Amoxicillin, Amoxicillin-Potassium Clavulanate - Bacteraemia, Endocarditis
Phase 4TerminatedUniversity of Santiago de Compostela402017-02-272022-05-24
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
Vancomycin, Ceftaroline, Daptomycin - Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis
Phase 4TerminatedHenry Ford Health System1002011-10-012023-05-03
Phase 4 Efficacy and Safety Study of CubicinĀ® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
daptomycin, daptomycin and gentamicin - Infective Endocarditis
Phase 4TerminatedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)242009-02-132021-02-02
Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis.
Daptomycin - Endocarditis, Bacterial
Phase 4TerminatedWeill Medical College of Cornell University62006-09-012017-05-03

Narrower conditions

Bacteremia (2)  ·  Endocarditis, Bacterial (2)  ·  Arthritis, Infectious (1)  ·  Gram-Positive Bacterial Infections (1)  ·  Osteomyelitis (1)  ·  Staphylococcal Infections (1)  ·  Toxemia (1)

Broader conditions

Cardiovascular Diseases (6)  ·  Heart Diseases (6)  ·  Infections (5)  ·  Bacterial Infections (4)  ·  Bacterial Infections and Mycoses (4)  ·  Cardiovascular Infections (2)  ·  Inflammation (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Sepsis (2)  ·  Systemic Inflammatory Response Syndrome (2)  ·  Arthritis (1)  ·  Bone Diseases (1)  ·  Bone Diseases, Infectious (1)  ·  Joint Diseases (1)

Interventions

Daptomycin (4)  ·  Amoxicillin (2)  ·  Ceftaroline (2)  ·  Linezolid (2)  ·  Vancomycin (2)  ·  Amoxicillin-Potassium Clavulanate Combination (1)  ·  Ampicillin (1)  ·  Anti-Bacterial Agents (1)  ·  Cefepime (1)  ·  Ceftriaxone (1)  ·  Cephalexin (1)  ·  Dicloxacillin (1)  ·  Drugs, Generic (1)  ·  Gentamicins (1)  ·  Injections (1)

Sponsors

Carmen Olmos Blanco (1)  ·  Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)  ·  Henry Ford Health System (1)  ·  University of Santiago de Compostela (1)  ·  Weill Medical College of Cornell University (1)  ·  West Virginia University (1)

Countries

United States (4)  ·  Spain (2)

Top investigators

Jose Vazquez, M.D. (1)  ·  Kyu Y Rhee, MD, PhD (1)  ·  Paula Bokesch, M.D. (1)  ·  Pedro Diz, MD, DDS, PhD (1)  ·  Vinay Badhwar, MD (1)

Results publications

PMID 16940094, PMID 18477269, PMID 20701619, PMID 27029851, PMID 32546269